title: Methodological and analytic considerations for blood biomarkers.
abstract: Biomarkers typically evolve from a research setting to use in clinical care as evidence for their independent contribution to patient management accumulates. This evidence relies heavily on knowledge of the preanalytical, analytical, and postanalytical characteristics of the biomarker's measurement. For the preanalytical phase, considerations such specimen type, acceptable anticoagulants for blood samples, biologic variation and stability of the biomarker under various conditions are key. The analytical phase entails critical details for development and maintenance of assays having performance characteristics that are "fit for service" for the clinical application at hand. Often, these characteristics describe the ability to measure minute quantities in the biologic matrix used for measurement. Although techniques such as mass spectrometry are used effectively for biomarker discovery, routine quantification often relies on use of immunoassays; early in development, the most common immunoassay used is the enzyme-linked immunosorbent assay format. As biomarkers evolve successfully, they will be adapted to large main laboratory platforms or, depending on the need for speed, point-of-care devices. Users must pay particular attention to performance parameters of assays they are considering for clinical implementation. These parameters include the limit of blank, a term used to describe the limit of analytical noise for an assay; limit of detection, which describes the lowest concentration that can reliably be discriminated from analytical noise; and perhaps most importantly, the limit of quantitation, which is the lowest concentration at which a biomarker can be reliably measured within some predefined specifications for total analytical error that is based on clinical requirements of the test. The postanalytical phase involves reporting biomarker values, which includes reporting units, any normalization factors, and interpretation. Standardization, a process that involves metrological traceability to a primary reference material and definitive measurement method, is important to assure that all biomarker values are transferable in the literature and across institutions. In the absence of standardization, assays can be harmonized using secondary reference materials so that biomarker values can be combined for meta-analysis and interpreted clinically with common reference and decision limit values.
authors: University of Maryland School of Medicine, Baltimore, MD, USA. rchristenson@umm.edu
authors: Robert H
authors: RH
authors: Christenson
authors: Show-Hong
authors: SH
authors: Duh
mesh_terms: D001681:Biological Assay / Q000592:standards*; D015415:Biomarkers / Q000097:blood*; D035843:Biomedical Research / Q000592:standards*; D017408:Guidelines as Topic; D006801:Humans; D057230:Limit of Detection; D011237:Predictive Value of Tests; D011379:Prognosis; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards*
chemical_list: D015415:Biomarkers